1248 Management LLC Lowers Stake in Edwards Lifesciences Corporation $EW

Key Points

• 1248 Management LLC reduced its stake in Edwards Lifesciences by 24.5%, selling 4,050 shares in the first quarter, leaving them with 12,448 shares valued at approximately $902,000.
• Edwards Lifesciences reported a quarterly revenue of $1.53 billion, exceeding analyst expectations of $1.49 billion, along with an earnings per share of $0.67, beating the consensus estimate of $0.62.
• Institutional investors collectively hold 79.46% of Edwards Lifesciences' stock, reflecting strong interest from large investment firms.

1248 Management LLC trimmed its position in Edwards Lifesciences Corporation (NYSE:EW - Free Report) by 24.5% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 12,448 shares of the medical research company's stock after selling 4,050 shares during the quarter. 1248 Management LLC's holdings in Edwards Lifesciences were worth $902,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds have also added to or reduced their stakes in the stock. Paloma Partners Management Co purchased a new position in Edwards Lifesciences during the 1st quarter valued at $346,000. Focus Partners Advisor Solutions LLC increased its position in Edwards Lifesciences by 76.2% during the 1st quarter. Focus Partners Advisor Solutions LLC now owns 7,389 shares of the medical research company's stock valued at $535,000 after purchasing an additional 3,195 shares during the period. Graham Capital Management L.P. purchased a new position in Edwards Lifesciences during the 1st quarter valued at $1,082,000. MAI Capital Management increased its position in Edwards Lifesciences by 32.7% during the 1st quarter. MAI Capital Management now owns 85,927 shares of the medical research company's stock valued at $6,228,000 after purchasing an additional 21,192 shares during the period. Finally, GKV Capital Management Co. Inc. increased its position in Edwards Lifesciences by 1.6% during the 1st quarter. GKV Capital Management Co. Inc. now owns 12,495 shares of the medical research company's stock valued at $906,000 after purchasing an additional 200 shares during the period. 79.46% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In related news, insider Larry L. Wood sold 8,950 shares of the firm's stock in a transaction on Monday, August 18th. The stock was sold at an average price of $78.06, for a total value of $698,637.00. Following the completion of the sale, the insider directly owned 206,900 shares in the company, valued at $16,150,614. This trade represents a 4.15% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, VP Daniel J. Lippis sold 4,114 shares of the firm's stock in a transaction on Monday, July 28th. The stock was sold at an average price of $79.46, for a total value of $326,898.44. Following the completion of the sale, the vice president owned 22,002 shares of the company's stock, valued at approximately $1,748,278.92. This represents a 15.75% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 22,014 shares of company stock valued at $1,698,844. Insiders own 1.29% of the company's stock.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on the stock. Royal Bank Of Canada boosted their price objective on shares of Edwards Lifesciences from $85.00 to $89.00 and gave the company an "outperform" rating in a research report on Friday, July 25th. The Goldman Sachs Group reaffirmed a "buy" rating on shares of Edwards Lifesciences in a research report on Friday, July 25th. William Blair upgraded shares of Edwards Lifesciences to a "strong-buy" rating in a research note on Friday, July 25th. Dbs Bank upgraded shares of Edwards Lifesciences to a "hold" rating in a research note on Monday, June 2nd. Finally, Canaccord Genuity Group upped their price target on shares of Edwards Lifesciences from $75.00 to $81.00 and gave the stock a "hold" rating in a research note on Friday, July 25th. Three investment analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating, ten have given a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average price target of $85.90.

Edwards Lifesciences Stock Performance

Shares of NYSE EW traded down $0.07 during midday trading on Friday, hitting $80.89. 2,283,330 shares of the company's stock traded hands, compared to its average volume of 3,558,037. Edwards Lifesciences Corporation has a 1 year low of $64.00 and a 1 year high of $83.00. The stock has a market capitalization of $47.49 billion, a price-to-earnings ratio of 11.64, a price-to-earnings-growth ratio of 3.91 and a beta of 1.07. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.87 and a current ratio of 4.68. The firm has a fifty day moving average of $78.77 and a 200 day moving average of $75.21.

Edwards Lifesciences (NYSE:EW - Get Free Report) last released its earnings results on Thursday, July 24th. The medical research company reported $0.67 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.62 by $0.05. The company had revenue of $1.53 billion during the quarter, compared to analyst estimates of $1.49 billion. Edwards Lifesciences had a net margin of 72.96% and a return on equity of 15.01%. The firm's quarterly revenue was up 11.9% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.70 EPS. Edwards Lifesciences has set its Q3 2025 guidance at 0.540-0.60 EPS. FY 2025 guidance at 2.400-2.500 EPS. On average, analysts forecast that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current year.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.